These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 24641467)

  • 1. Malignant melanoma in a patient with Crohn´s disease and treated with anti-TNF alpha.
    Alcalde-Vargas A; Trigo-Salado C; Leo-Carnerero E; Lorente-Lavirgen AI
    Rev Esp Enferm Dig; 2013; 105(10):639-40. PubMed ID: 24641467
    [No Abstract]   [Full Text] [Related]  

  • 2. Multiple cutaneous malignancies arising in a patient with Crohn disease treated with concomitant azathioprine and antitumour necrosis factor-alpha.
    Fogo AJ; Hunt JB; Clement M
    Clin Exp Dermatol; 2010 Oct; 35(7):793-5. PubMed ID: 20345989
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical and histologic findings in patients with uveal melanomas after taking tumor necrosis factor-α inhibitors.
    Damento G; Kavoussi SC; Materin MA; Salomão DR; Quiram PA; Balasubramaniam S; Pulido JS
    Mayo Clin Proc; 2014 Nov; 89(11):1481-6. PubMed ID: 25444484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System.
    McKenna MR; Stobaugh DJ; Deepak P
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):267-71. PubMed ID: 25267954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endoscopic Complete Remission of Crohn Disease After Anti-Tumor Necrosis Factor-α Therapy: CT Enterographic Findings and Their Clinical Implications.
    Kim C; Park SH; Yang SK; Ye BD; Park SH; Lee JS; Kim HJ; Kim AY; Ha HK
    AJR Am J Roentgenol; 2016 Jun; 206(6):1208-16. PubMed ID: 26998628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Skin cancer associated with commonly prescribed drugs: tumor necrosis factor alpha inhibitors (TNF-αIs), angiotensin-receptor blockers (ARBs), phosphodiesterase type 5 inhibitors (PDE5Is) and statins -weighing the evidence.
    Nardone B; Orrell KA; Vakharia PP; West DP
    Expert Opin Drug Saf; 2018 Feb; 17(2):139-147. PubMed ID: 29103328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Crohn disease during anti-TNF-alpha therapy in a child with juvenile idiopathic arthritis.
    Ruemmele FM; Prieur AM; Talbotec C; Goulet O; Schmitz J
    J Pediatr Gastroenterol Nutr; 2004 Aug; 39(2):203-6. PubMed ID: 15269630
    [No Abstract]   [Full Text] [Related]  

  • 8. Reactivation tuberculosis in a patient with anti-TNF-alpha treatment.
    Núñez Martínez O; Ripoll Noiseux C; Carneros Martín JA; González Lara V; Gregorio Marañón HG
    Am J Gastroenterol; 2001 May; 96(5):1665-6. PubMed ID: 11374737
    [No Abstract]   [Full Text] [Related]  

  • 9. Multiple and fulminant cutaneous squamous cell carcinomas in a Crohn's disease patient treated with immunosuppressants and adalimumab.
    Nancey S; Boschetti G; Cotte E; Cathey-Javouhay A; Laidet M; Chichery A; Francois Y; Glehen O; Flourié B
    Inflamm Bowel Dis; 2011 Apr; 17(4):1060-1. PubMed ID: 21391289
    [No Abstract]   [Full Text] [Related]  

  • 10. Cryptosporidiosis in a patient with Crohn's disease under anti-TNF treatment.
    Miranda A; De Musis C; Sgambato D; De Mauro D; Picascia D; Avallone L; Romano L; D'Armiento FP; Romano M
    Acta Gastroenterol Belg; 2019; 82(3):447-448. PubMed ID: 31566337
    [No Abstract]   [Full Text] [Related]  

  • 11. Every fourth patient with Crohn's disease has anti-TNF dependency.
    Molnár T; Farkas K; Nyári T; Nagy F; Szepes Z; Wittmann T
    Aliment Pharmacol Ther; 2011 Aug; 34(3):400-1. PubMed ID: 21726253
    [No Abstract]   [Full Text] [Related]  

  • 12. Tumor necrosis factor-α blockade and development of uveal melanoma: expected adverse effect or just coincidence?
    Sato T
    Mayo Clin Proc; 2014 Nov; 89(11):1467-70. PubMed ID: 25444483
    [No Abstract]   [Full Text] [Related]  

  • 13. Retrobulbar optic neuritis associated with infliximab in a patient with Crohn disease.
    Strong BY; Erny BC; Herzenberg H; Razzeca KJ
    Ann Intern Med; 2004 Apr; 140(8):W34. PubMed ID: 15096366
    [No Abstract]   [Full Text] [Related]  

  • 14. Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease.
    Conklin LS; Cohen B; Wilson L; Cuffari C; Oliva-Hemker M
    Nat Rev Gastroenterol Hepatol; 2010 Mar; 7(3):174-7. PubMed ID: 20203680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review article: loss of response to anti-TNF treatments in Crohn's disease.
    Ben-Horin S; Chowers Y
    Aliment Pharmacol Ther; 2011 May; 33(9):987-95. PubMed ID: 21366636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Locoregional use of TNF (tumor necrosis factor) in the treatment of malignant melanoma].
    Lejeune F
    Pathol Biol (Paris); 1990 Oct; 38(8):883-4. PubMed ID: 1703292
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-tumor necrosis factor alpha: Crohn's disease guided missile.
    Bitton A
    Inflamm Bowel Dis; 1998 May; 4(2):173-4. PubMed ID: 9589305
    [No Abstract]   [Full Text] [Related]  

  • 18. Levodopa therapy and malignant melanoma.
    Sober AJ; Wick MM
    JAMA; 1978 Aug; 240(6):554-5. PubMed ID: 671667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab (Remicade) and increased incidence of development of basal cell carcinoma.
    Gaines-Cardone E; Hale EK
    J Drugs Dermatol; 2012 May; 11(5):655-6. PubMed ID: 22527438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanoma.
    Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Kroon B; Gérain J; Rosenkaimer F; Schmitz P
    Circ Shock; 1994 Aug; 43(4):191-7. PubMed ID: 7895325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.